Table 1 Baseline characteristics and outcomes of patients with advanced metastatic cancer who had prolonged response to immunotherapy
Case 1 | Case 2 | Case 3 | Case 4 | Case 5 | |
|---|---|---|---|---|---|
Age at diagnosis | 20s | 50s | 30s | 70s | 50s |
Sex | Female | Male | Female | Male | Female |
Diagnosis | Rectal adenocarcinoma | Neuroendocrine carcinoma | Colon adenocarcinoma | Prostate adenocarcinoma | Neuroendocrine carcinoma |
Prior therapies | - Low anterior resection - FOLFIRINOX - Lung wedge resection - Capecitabine/bevacizumab | - Carboplatin/ - etopsoide - Right hemicolectomy - FOLFIRINOX | - Total colectomy - FOLFOX - Abdominal mass resection - FOLFOX/bevacizumab - FOLFIRI/bevacizumab - CRS + HIPEC - Irinotecan - CRS + HIPEC - FOLFIRI/bevacizumab - Anti-Globo H monoclonal antibody - 4-1BB agonist, cetuximab and irinotecan | - Androgen deprivation therapy - Sipuleucel-T - Abiraterone acetate/apalutamide/prednisone (clinical trial) - Cabazitaxel/carboplatin | - Total abdominal hysterectomy/bilateral salpingo-oophrectomy, node dissection, and appendectomy - Vincristine and doxorubicin - Radiation therapy - Carboplatin/etoposide - Temozolomide - Everolimus - Peptide-drug conjugate - Carboplatin/etoposide |
Time (diagnosis to start of anti-CTLA4/ PD1), years | 3 | 1.5 | 3.5 | 4.5 | 11 |
ECOG PS | 0 | 1 | 1 | 1 | 1 |
LDH | Normal | Elevated | Not evaluated | Normal | Elevated |
Genetic mutations | FBXW7 G423R, KRAS G12D, TP53 R282W, APC N942fs, and APC E1309* | KRAS G12D and RAD50 E995fs*2 | KRAS G12D, PIK3CA E545K, and CHEK2 T367fs*15 | PIK3CA N1044K | PIK3CA Y1021H |
Microsatellite/mismatch repair status | MSS | MSS | MSS | dMMR | ND |
PD-L1 status | Negative | Negative | Negative | ND | ND |
TMB | ND | 2.6 mutations/mb | 3.2 mutations/mb | ND | ND |
No. of cycles with CTLA4/PD1 | 11 | 4 | 4 | 1 | 7 |
No. of cycles of PD1 maintenance | 6 | 2 | 4 | 0 | 35 |
Best response per CT scans | PR | PR | PR | PR | PR |
Best response per PET/CT | CR | CR | PR | Not done | CR |
Grade 3-4 irAEs | Pneumonitis, colitis, esophagitis | Gastritis/duodenitis | Colitis | Transaminitis | None |
Tumor markers | CEA at baseline: 59.9 CEA at end of treatment: 3.2 | ND | CEA at baseline: 6.4 CEA at end of treatment: 4.1 | PSA at baseline: 19.1 PSA at end of treatment: 0.1 | ND |
PFS | 34+ months | 68 months | 38+ months | 68+ months | 69+ months |
